Terms: = Colorectal cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
1192 results:
1. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of colorectal cancer in Tibet].
Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
[TBL] [Abstract] [Full Text] [Related]
2. Tropomyosin 2 Regulates Tumor Cell Proliferation, Immune Suppression, and Activation of the JNK Signaling Pathway in Colitis-Associated cancer (CAC).
Sun A; Ge J; Ding K; Gao Z; Zhang Y
Discov Med; 2024 Apr; 36(183):778-787. PubMed ID: 38665026
[TBL] [Abstract] [Full Text] [Related]
3. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
4. Loss of Y in regulatory T lymphocytes in the tumor micro-environment of primary colorectal cancers and liver metastases.
Wójcik M; Juhas U; Mohammadi E; Mattisson J; Drężek-Chyła K; Rychlicka-Buniowska E; Bruhn-Olszewska B; Davies H; Chojnowska K; Olszewski P; Bieńkowski M; Jankowski M; Rostkowska O; Hellmann A; Pęksa R; Kowalski J; Zdrenka M; Kobiela J; Zegarski W; Biernat W; Szylberg Ł; Remiszewski P; Mieczkowski J; Filipowicz N; Dumanski JP
Sci Rep; 2024 Apr; 14(1):9458. PubMed ID: 38658633
[TBL] [Abstract] [Full Text] [Related]
5. Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity.
Xiang Z; Lu J; Rao S; Fu C; Yao Y; Yi Y; Ming Y; Sun W; Guo W; Chen X
Theranostics; 2024; 14(6):2290-2303. PubMed ID: 38646651
[No Abstract] [Full Text] [Related]
6. [Organ preservation in locally advanced colorectal cancer with microsatellite instability-high after immunotherapy].
Hong ZG; Xiao BY; Ding PR
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):353-358. PubMed ID: 38644240
[TBL] [Abstract] [Full Text] [Related]
7. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-pd-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
8. Construction and verification of a histone deacetylases-related prognostic signature model for colon cancer.
Hao L; Lu W; Wu J; Chen Y; Xu D; Wang P
Sci Rep; 2024 Apr; 14(1):8983. PubMed ID: 38637684
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer.
Zhang W; Chen L; Liu J; Chen B; Shi H; Chen H; Qi H; Wu Z; Mao X; Wang X; Huang Y; Li J; Yu Z; Zhong M; Wang T; Li Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):114. PubMed ID: 38627815
[TBL] [Abstract] [Full Text] [Related]
10. Complete remission in a pretreated, microsatellite-stable,
He L; Li H; Wang Y; Li W; Gao L; Xu B; Hu J; He P; Pu W; Sun G; Wang Z; Han Q; Liu B; Chen H
Front Immunol; 2024; 15():1354613. PubMed ID: 38617840
[TBL] [Abstract] [Full Text] [Related]
11. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
[TBL] [Abstract] [Full Text] [Related]
12. GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression.
Khan B; Chen M; Wang H; Khan A; Hussain S; Shi J; Yang L; Hou Y
Eur J Pharmacol; 2024 Jun; 972():176565. PubMed ID: 38599309
[TBL] [Abstract] [Full Text] [Related]
13. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in colorectal cancer Immunotherapy.
Lv Q; Yang H; Wang D; Zhou H; Wang J; Zhang Y; Wu D; Xie Y; Lv Y; Hu L; Wang J
J Med Chem; 2024 Apr; 67(8):6854-6879. PubMed ID: 38593344
[TBL] [Abstract] [Full Text] [Related]
14. Expressions of CXCR3 and pd-1 on T cells and their clinical relevance in colorectal cancer.
Wang S; Zhang Y; Chen G; Zhao P; Wang X; Xu B; Yuan L
Int Immunopharmacol; 2024 May; 132():111988. PubMed ID: 38583239
[TBL] [Abstract] [Full Text] [Related]
15. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
[TBL] [Abstract] [Full Text] [Related]
16. Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-pd-1 antibodies in combination with radiotherapy.
Chen JY; Lin PY; Hong WZ; Yang PC; Chiang SF; Chang HY; Ke TW; Liang JA; Chen WT; Chao KSC; Huang KC
Cancer Immunol Immunother; 2024 Apr; 73(5):92. PubMed ID: 38564022
[TBL] [Abstract] [Full Text] [Related]
17. Associations of pd-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
18. Exploring the clinical significance of IL-38 correlation with pd-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
[TBL] [Abstract] [Full Text] [Related]
19. Precursor exhausted CD8
Huang H; Ge J; Fang Z; Wu S; Jiang H; Lang Y; Chen J; Xiao W; Xu B; Liu Y; Chen L; Zheng X; Jiang J
Front Immunol; 2024; 15():1362140. PubMed ID: 38510246
[TBL] [Abstract] [Full Text] [Related]
20. Serum iron element: A novel biomarker for predicting pd-1 immunotherapy efficacy.
Luan F; Wang J; Liu L; Liu B; Li F; Zhao J; Lai J; Jiang F; Xu W; Zhang Z; Ran P; Shu Y; Yang Z; Fu G
Int Immunopharmacol; 2024 Apr; 131():111823. PubMed ID: 38508094
[TBL] [Abstract] [Full Text] [Related]
[Next]
